PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma

Author： Madan Ravi A Arlen Philip M Gulley James L

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.7, Iss.4, 2007-04, pp. : 543-554

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer

By Sangha Randeep North Scott

Expert Opinion on Biological Therapy, Vol. 7, Iss. 11, 2007-11 ,pp. : 1723-1730

Informa Healthcare

Access to resources Recommend Favorite

Immunology of O-Glycosylated Proteins: Approaches to the Design of a MUC1 Glycopeptide-Based Tumor Vaccine

Current Protein and Peptide Science, Vol. 7, Iss. 4, 2006-08 ,pp. : 307-315

Bentham Science Publishers

Access to resources Recommend Favorite

Gene therapy as a vaccine for HIV-1

By Berkhout Ben Sanders Rogier W

Expert Opinion on Biological Therapy, Vol. 12, Iss. 10, 2012-10 ,pp. : 1315-1321

Informa Healthcare

Access to resources Recommend Favorite

CFTR expression does not influence glycosylation of an epitope-tagged MUC1 mucin in colon carcinoma cell lines

By Burdick M.D.

Glycobiology, Vol. 9, Iss. 4, 1999-04 ,pp. : 389-398

Oxford University Press

Access to resources Recommend Favorite

Adenovirus vaccine immunotherapy targeting WT1-expressing tumors

By Clarke Jeffrey M Morse Michael A Lyerly H Kim Clay Timothy Osada Tayuka

Expert Opinion on Biological Therapy, Vol. 10, Iss. 6, 2010-06 ,pp. : 875-883

Informa Healthcare

Access to resources Recommend Favorite